RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1160/TH15-12-0918
Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American Specialized Coagulation Laboratories
Financial support: NDZ has received research funding from Sekisui Diagnostics, Inc. The other authors declare no conflicts of interest related to the content of the manuscript.
Publikationsverlauf
Received:
02. Dezember 2015
Accepted after major revision:
26. März 2016
Publikationsdatum:
27. November 2017 (online)
Summary
In 2010–2012, the North American Specialized Coagulation Laboratory Association (NASCOLA) distributed 12 proficiency testing challenges to evaluate laboratory testing for protein S (PS). Results were analysed to assess the performance of PS activity, PS free antigen, and PS total antigen testing. Statistical analysis was performed on the numeric results and qualitative classification submitted for each method. There were 2,106 total results: 716 results from PS activity assays, 833 results from PS free antigen assays, and 557 results from PS total antigen assays. The three assay types performed well in the classification of five normal samples and nine abnormal samples, although certain PS activity methods were more likely to classify normal samples as abnormal and one PS total antigen assay was more likely to classify abnormal samples as normal. PS activity methods were affected by interfering substances such as heterozygous or homozygous factor V Leiden mutation (underestimation) and the anticoagulant drug rivaroxaban (overestimation). In conclusion, NASCOLA laboratories using a variety of PS assays performed well in the classification of clearly normal and abnormal samples. Laboratories performing PS activity assays should be aware of potential interferences in samples positive for FV Leiden or containing certain anticoagulant medications.
-
References
- 1 Goodwin AJ. et al. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med 2002; 126: 1349-1366.
- 2 Pintao MC. et al. Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study. Blood 2013; 122: 3210-3219.
- 3 Marlar RA, Gausman JN. Protein S abnormalities: a diagnostic nightmare. Am J Hematol 2011; 86: 418-421.
- 4 Marlar RA, Gausman JN. Laboratory testing issues for protein C, protein S, and antithrombin. Int J Lab Hematol 2014; 36: 289-295.
- 5 Hepner M, Karlaftis V. Protein S. Methods Mol Biol 2013; 992: 373-381.
- 6 Dykes AC. et al. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001; 113: 636-641.
- 7 Franchi F. et al. Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status. Thromb Res 2013; 132: e152-157.
- 8 Makris M. et al. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood 2000; 95: 1935-1941.
- 9 Moser KA. et al. Pitfalls in special coagulation testing: three illustrative case studies. Int J Lab Hematol 2013; 35: 334-338.
- 10 Libourel EJ. et al. Protein S type III deficiency is no risk factor for venous and arterial thromboembolism in 168 thrombophilic families: a retrospective study. Blood Coagul Fibrinolysis 2005; 16: 135-140.
- 11 Gandrille S. et al. Protein S deficiency: a database of mutations--summary of the first update. Thromb Haemost 2000; 84: 918.
- 12 Favaloro EJ. et al. Laboratory investigation of thrombophilia: the good, the bad, and the ugly. Semin Thromb Hemost 2009; 35: 695-710.
- 13 Jennings I. et al. Sensitivity of functional protein S assays to protein S deficiency: a comparative study of three commercial kits. J Thromb Haemost 2003; 01: 1112-1114.
- 14 Brouwer JL. et al. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol 2005; 128: 703-710.
- 15 Van Cott EM. et al. Protein S assays: an analysis of North American Specialized Coagulation Laboratory Association proficiency testing. Am J Clin Pathol 2005; 123: 778-785.
- 16 Mulder R. et al. Low cut-off values increase diagnostic performance of protein S assays. Thromb Haemost 2010; 104: 618-625.
- 17 Zoller B. et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523.
- 18
Press RD.
et al. Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management
of thromboembolic disorders. Arch Pathol Lab Med 2002; 126: 1304-1318.
MissingFormLabel
- 19 Mani H. et al. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013; 109: 127-136.
- 20 Hillarp A. et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost 2014; 12: 1545-1553.
- 21 Adcock DM. et al. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol 2013; 139: 102-109.
- 22 Kim YA. et al. The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays. Int J Lab Hematol 2015; 37: e81-4.